NCT03116152View on ClinicalTrials.gov

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

October 2, 2019

Study Completion Date

October 2, 2019

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
BIOLOGICAL

IBI308

IBI308 200mg Intravenous drip every three weeks；

DRUG

paclitaxel/ irinotecan

paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks

Trial Locations (1)

10071

The Fifth Medical Center of PLA Ceneral Hospital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03116152 - Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | Biotech Hunter | Biotech Hunter